Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siATP5G3 is a small interfering RNA (siRNA) that targets the mRNA of the ATP5G3 gene, which encodes subunit C3 of the mitochondrial ATP synthase complex (Complex V). By silencing ATP5G3 expression, this agent is used in research to investigate mitochondrial function and cell death pathways. In cervical carcinoma (HeLa) cell models, siATP5G3-mediated knockdown has been shown to enhance cytotoxicity induced by sodium nitroprusside (SNP). This effect is mediated through the activation of the p38 MAPK signaling pathway and the subsequent modulation of pro-apoptotic and anti-apoptotic proteins like Bax and Bcl-xL, leading to autophagic or lysosome-associated cell death. It serves as a research tool to demonstrate the protective role of ATP5G3 against oxidative stress-induced cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siATP5G3.